GPT and metabolic dysfunction-associated steatotic liver disease: Treatment of NAFLD mice with AT (20 mg/kg) led to a slight decrease in serum ALT and AST activities (19.87% and 23.25%, respectively) compared with untreated NAFLD mice; however, these changes were not statistically significant (p > 0.05; Figure 2).